Robotics ETF Tianhong(159770) had a trading volume of nearly 80 million yuan last Friday, ranking first among similar products in the Shenzhen market. Domestic medical robots completed their first clinical application in Hong Kong.

As of the close on April 3, 2026, the Robot ETF Tianhong(159770) traded 78.1087 million yuan, ranking first among the same target in the Shenzhen market. The tracked CSI Robot Index(H30590) declined by 0.95%. In terms of constituent stocks, gains and losses were mixed, with Tianzhun Technology leading up 5.86%, KuaiKe Intelligent up 5.67%, and Kerui Technology up 4.93%.

As of April 3, the Robot ETF Tianhong(159770) has grown by 3.83B yuan in scale over the past year, with a half-year increase of 497 million shares, achieving significant growth.

【Product Highlights】

The Robot ETF Tianhong(159770) closely tracks the CSI Robot Index, focusing on artificial intelligence hardware terminals, covering core targets across the entire robot industry chain.

【Related Products】

Robot ETF Tianhong(159770), linked to OTC funds(A: 014880; C: 014881).

【Hot Events】

China develops a medical assistive robot that completes its first clinical application

Recently, the core technology development team from the Institute of Automation, Chinese Academy of Sciences, successfully completed the first clinical application of a robot-assisted transcatheter tricuspid valve replacement system in Hong Kong. The surgery involved precisely implanting a transcatheter tricuspid valve in a patient with severe tricuspid regurgitation. Postoperative assessment showed the tricuspid regurgitation disappeared, and the patient was in good condition.

It is understood that this system, called the “Robot-Assisted Transcatheter Tricuspid Valve Replacement(TTVR) System,” integrates high-precision motion control, active safety constraints, and intelligent navigation technology to achieve stable, delicate instrument control, ensuring the safety and reliability of key operational steps. Compared to traditional manual operations, the robot-assisted system is expected to reduce complications caused by slight hand tremors or operational variations, improve the accuracy of valve implantation, and shorten surgical time.

【Institutional Viewpoint】

According to Saidi Data, the global humanoid robot market shipment volume is approximately 17,000 units in 2025, entering an initial scale-up phase. Essentially, humanoid robots and new energy vehicles share a high degree of technological commonality, both following a “perception-decision-execution” closed-loop logic and an industrialization path of “concept release-prototype verification-small batch trial production-large-scale mass production.”

By comparing supply chain development, policy guidance, and capital markets, PuYin International believes that the current stage of humanoid robots is roughly comparable to the development phase of new energy vehicles between 2018 and 2020, with a potential explosion in shipments expected by 2026. The dual pressures of an aging population and rising labor costs serve as the fundamental driving forces for the long-term development of the humanoid robot industry.

【More Products】

MACD golden cross signal formed, these stocks are on a strong upward trend!

Massive information, precise analysis, all on Sina Finance APP